$1.60
-0.15-8.57%
Last update: Oct 30, 7:16 PM
CervoMed Inc (CRVO) Stock Price, Quote, News & History
CRVONASDAQ
CervoMed reports a promising reduction in neuronal damage biomarkers during the first 12 weeks of its Phase 2a trial for neflamapimod.
You can purchase shares of CervoMed (NASDAQ:CRVO) through any online brokerage.
Other companies in CervoMed’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
CervoMed has a consensus price target of $26.56.
The stock price for CervoMed (NASDAQ: CRVO) is $1.73 last updated October 30, 2026 at 7:16 PM EDT.
There are no upcoming dividends for CervoMed.
CervoMed does not have any upcoming earnings scheduled.
There is no upcoming split for CervoMed.
CervoMed is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the...
